Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases

Affiliations

Young-Ho Kim. Intest Res. 2018 Oct.

. 2018 Oct;16(4):507-508.

doi: 10.5217/ir.2018.00136. Epub 2018 Oct 25.

¹ Department of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

No abstract available

Conflict of interest statement

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.
Wei SC, Tung CC, Weng MT, Wong JM. Wei SC, et al. Intest Res. 2018 Oct;16(4):546-553. doi: 10.5217/ir.2018.00052. Epub 2018 Oct 10. Intest Res. 2018. PMID: 30301339 Free PMC article.

1. Lee KM. Fecal biomarkers in inflammatory bowel disease. Intest Res. 2013;11:73–78.
1. Wei SC. Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease? Intest Res. 2016;14:293–294. - PMC - PubMed
1. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817–1826. e2. - PMC - PubMed
1. Arai T, Takeuchi K, Miyamura M, et al. Level of fecal calprotectin correlates with severity of small bowel Crohn’s disease, measured by balloon-assisted enteroscopy and computed tomography enterography. Clin Gastroenterol Hepatol. 2017;15:56–62. - PubMed
1. Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohn’s disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis. 2017;23:2027–2034. - PubMed